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Objective
Outline the clinical course of a patient with mast cell
gastroenteritis and describe typical presentation,
interpretation of results, and suggested treatments for
this evolving diagnosis.

Case Presentation
History of Presenting Illness
38 y/o woman with hx of RA and MCTD, has
several recent hospitalizations for colitis/enteritis of
unknown etiology.

Results
In hopes of discovering a cause for the patient’s
symptoms, empiric treatments were held off for almost
a week.

Differential Diagnosis
•
•
•
•

Inflammatory bowel disease
Irritable bowel disease
Small vessel vasculitis
Hereditary angioedema

• Acute intermittent porphyria
• Eosinophilic gastroenteritis
• Intra-abdominal TB

Radiographic Imaging
Image 1-CT Abdomen/Pelvis

Current constellation of symptoms:
• 4 days of nausea and intractable vomiting
• new-onset rectal fullness with constipation for 4 days
• mucoid rectal discharge for 2 days
Symptoms that started 3 months ago:
• Intermittent intractable vomiting, diarrhea, and
abdominal pain
• Complete resolution of symptoms in between
episodes
• 3 different admissions at 3 different hospitals
Social History
Negative for drug use including marijuana. Travel
history includes frequent travel for long periods of time
to Mexico to visit family.
Physical Exam
Patient had mild tachycardia but had an otherwise
benign exam including a normal rectal. Clear mucoid
discharge was seen on her bed sheets.

Sigmoidoscopy biopsies tested post hoc for eosinophilic
and mast cell gastroenteritis.

Multifocal small bowel thickening demonstrated
in patient’s abdominal imaging. At the current
level two foci of thickening can be seen (see
arrows).

Severe rectal wall thickening (see arrow) seen in
the setting of constipation on admission. Similar
changes observed in more proximal segments of
the colon in previous images

Image 2-Flexible Sigmoidoscopy
Direct visualization of the rectum shows no signs
of inflammation. Other than nonspecific swelling
no other findings were found on sigmoidoscopy.

Workup during admission
• Normal CBC with diff
• 2+ protein and 3+ blood on UA
• ESR 10 and CRP 2.4
• Compliment C3/C4 low, with normal C1 esterase
• Repeat abdominal imaging showed diffuse small
bowel and colon inflammatory wall thickening with
severe rectal wall thickening.
• Flexible sigmoidoscopy showed significantly
congested rectal mucosa and a patch of mildly
erythematous mucosa
• Rheumatologic workup negative for acute flare
• Mixed connective tissue disease confirmed with no
new findings

Image courtesy of Ramsay et al.

Treatment Pathway
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degranulation

• Rectal hydrocortisone quickly helped to relieve
constipation and mucosal discharge
• Empiric high-dose IV methylprednisolone for 48-36
hours
• Initiation of PO budesonide once tolerating oral
intake

Discussion

Image 3-CD117 Stain

Example of a positive CD117 stain for
mast cells. Testing is done on a biopsy of
the gastrointestinal tissues and cells are
seen within the lamina propria.

• No eosinophilic infiltration was seen
• A total of 26 CD117+ mast cells per hpf were
described in lamina propria
• No evidence of systemic mastocytosis during
admission suggesting an intraluminal cause of
observed pathology

Treatments

Direct Imaging

Diagnostic Workup
Workup prior to admission
• Positive lactoferrin
• QuantiFERON Gold TB screen positive
• CT scan showing inflammatory small and large bowel
patterns consistent with inflammatory bowel disease
• Upper and lower endoscopy with biopsies—
inconclusive studies without signs of inflammation
• Exploratory laparoscopy within normal limits
• Serum inflammatory markers inconclusive

• Colitis ruled out on endoscopy and biopsies
• Vasculitis was ruled out due to symptoms being
localized to GI system only and no signs of vasculitis
seen on rectal biopsy
• Proteinuria and hematuria found to be secondary to
menstruation and not part of a vasculitis
• No signs of serositis or rheumatologic flare found
• Underlying mixed connective tissue disease
confirmed on rheumatologic workup but not likely
contributing to GI symptoms
• Hereditary angioedema unlikely with normal C1
esterase

I

II

• Mast cells in the GI tract can cause intractable
vomiting and diffuse small and large bowel
inflammation, as demonstrated in this case1,2
• Activation of mast cells may be the primary cause of
GI pathology, or secondary to another process3
• Within the lamina propria mast cells are stained with
CD117 and found with an average of 13 cells/hpf4
• No specific criteria exists at this time for mast cell
gastroenteritis (MCG), but one study suggests a
cutoff of 20 cells/hpf within the lamina propria4
• Most commonly proposed cause of MCG is food
allergen4
• Treatments suggested for GI mast cell activation
include H2 antihistamines, cromolyn, antileukotriene
drugs, and budesonide1,4

Steroids

References
III

Cromolyn
Ketotifen
Quercetin

IV
Histamine antagonists like
H2 blockers
Protease antagonists
Leukotriene antagonists like
montelukast
Image courtesy of Graham et al.
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